Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a)

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00078713" target="_blank" >RIV/00023001:_____/19:00078713 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/19:10402051 RIV/00064203:_____/19:10402051

Result on the web

<a href="https://reader.elsevier.com/reader/sd/pii/S1567568819300595?token=9A029E9726EA063036DB8F6689F7A32D908EF25160CD28DE1962B2A585ACFC84A0588C29797C58FFB1F1AD2237C31C9C" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1567568819300595?token=9A029E9726EA063036DB8F6689F7A32D908EF25160CD28DE1962B2A585ACFC84A0588C29797C58FFB1F1AD2237C31C9C</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.036" target="_blank" >10.1016/j.atherosclerosissup.2019.08.036</a>

Result language

angličtina

Original language name

Influence of lipoprotein apheresis on circulating plasma levels of miRNAs in patients with high Lp(a)

Original language description

Background: Lipoprotein apheresis (LA) is a well-established therapy for lowering lipid levels in serious cases of dyslipidaemia, including high levels of lipoprotein(a) [Lp(a)]. This method lowers both LDL cholesterol and Lp(a) by more than 60% in most of patients; however, because randomized clinical studies could be extremely difficult, also other markers of the effect of this procedures on vascular health are of importance. Therefore, in addition to changes in plasma lipids and Lp(a) during LA, we also analysed the response of biomarkers associated with vascular integrity: small non-coding microRNAs (miRNAs). Materials and methods: We analysed the changes in miRNAs in two women (age 70 and 72 years) with clinically manifest extensive and progressive atherosclerotic disease and high levels of Lp(a) and with different clinical course who were treated by LA. In both women we analysed changes of 175 circulating plasma miRNAs using pre-defined serum/plasma focus panels at the beginning of and one year after the therapy. Results: In addition to reduced levels of plasma lipids and Lp(a), circulating plasma levels of miR-193a-5p; -215-5p; -328-3p; -130a-3p; -362-3p; -92b-3p decreased, and levels of miR-125a-5p; -185-5p; -106a-5p; -320b; -19a increased (all P &lt; 0.05) in both women. Moderate differences were found between both women with regard to the different course of atherosclerotic disease. Conclusions: Long-term LA substantially changes circulating plasma miRNAs associated with vascular integrity reflected different clinical course in both women. If confirmed, this approach could improve the assessment of the effectiveness of this therapy on an individual basis. (C) 2019 Elsevier B.V. All rights reserved.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

<a href="/en/project/NV17-28882A" target="_blank" >NV17-28882A: Genetic plymorphisms, MicroRNAs and bioindicators of activity: interrelations in the diagnostics and therapy of severe familial hypercholesterolemia</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Atherosclerosis supplements

ISSN

1567-5688

e-ISSN

—

Volume of the periodical

40

Issue of the periodical within the volume

December

Country of publishing house

IE - IRELAND

Number of pages

5

Pages from-to

12-16

UT code for WoS article

000501345000003

EID of the result in the Scopus database

2-s2.0-85076126166